Skip to main content
Erschienen in: Medical Oncology 9/2015

01.09.2015 | Original Paper

Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma

verfasst von: Yanli Xiong, Jia Liu, Shu Chen, Qian Zhou, Wenjing Xu, Chen Tang, Yonghong Chen, Mei Yang, Xin Lei

Erschienen in: Medical Oncology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to compare the effect of combined external beam radiotherapy (EBRT) and Californium (Cf)-252 neutron intracavity brachytherapy (ICBT) on cervical squamous versus adenocarcinoma. A total of 106 patients with stage IB–IIIB cervical cancer were accrued between January 2005 and May 2011 and divided into squamous cell carcinoma (SCC) and adenocarcinoma (AC) as a pair with 53 patients in each group according to tumor size, stage, age, and hemoglobin level using matched-pair design. The whole pelvic EBRT was performed with 2 Gy/fraction, 4 fractions/week. The total dose was 48–54 Gy (the center of whole pelvic field was blocked by 4 cm in width after 20–36 Gy). Cf-252 neutron ICBT was delivered with 11 and 12 Gy-eq/f with the total dose at point A of 44 and 48 Gy-eq for SCC and AC patients, respectively. The mean follow-up time was 43 months. The 5-year LC, OS, DFS, LAC rates, and mean survival time were 66.0, 56.6, 52.8.0, 17.0 %, and 76.4 ± 6.2 months, respectively, for AC patients, whereas they were 81.1, 69.8, 67.9, 11.3 %, and 93.3 ± 4.3 months, respectively, for SCC patients. Furthermore, the early treatment toxicity was mild in both groups, the late treatment complications were mainly radiation-induced proctitis and cystitis, and there were no grade 3 or higher complications. Although the combination of Cf-252 neutron ICBT and EBRT was effective in both histology types of cervical cancer, a more aggressive strategy is needed to control cervical AC.
Literatur
2.
Zurück zum Zitat Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix–worldwide. Asian Pac J Cancer Prev. 2009;4(10):645–50. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix–worldwide. Asian Pac J Cancer Prev. 2009;4(10):645–50.
3.
Zurück zum Zitat Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician. 2000;61(5):1369–76.PubMed Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician. 2000;61(5):1369–76.PubMed
4.
Zurück zum Zitat Kumar V et al. Robbins basic pathology, 8th ed. New York: Saunders Elsevier; 2007. pp. 718–721. Kumar V et al. Robbins basic pathology, 8th ed. New York: Saunders Elsevier; 2007. pp. 718–721.
5.
Zurück zum Zitat Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol. 2010;116(1):140–6.CrossRefPubMed Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol. 2010;116(1):140–6.CrossRefPubMed
6.
Zurück zum Zitat Smith HO, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000;78(2):97–105.CrossRefPubMed Smith HO, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000;78(2):97–105.CrossRefPubMed
7.
Zurück zum Zitat Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. The Lancet. 2001;357(9267):1490–3.CrossRef Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. The Lancet. 2001;357(9267):1490–3.CrossRef
8.
Zurück zum Zitat Mabuchi S, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127(1):114–20.CrossRefPubMed Mabuchi S, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127(1):114–20.CrossRefPubMed
9.
Zurück zum Zitat Green JA, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet. 2001;358(9284):781–6.CrossRef Green JA, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet. 2001;358(9284):781–6.CrossRef
10.
Zurück zum Zitat Rose PG. Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm? Gynecol Oncol. 2012;125(2):285–6.CrossRefPubMed Rose PG. Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm? Gynecol Oncol. 2012;125(2):285–6.CrossRefPubMed
11.
Zurück zum Zitat Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125(2):292–6.CrossRefPubMed Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125(2):292–6.CrossRefPubMed
12.
13.
Zurück zum Zitat Shinglefon HM, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer Cell. 1995;10(suppl 76):1948–55.CrossRef Shinglefon HM, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer Cell. 1995;10(suppl 76):1948–55.CrossRef
14.
Zurück zum Zitat Chen JL, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet Gynecol Scand. 2014;93(7):661–8.CrossRefPubMed Chen JL, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet Gynecol Scand. 2014;93(7):661–8.CrossRefPubMed
15.
Zurück zum Zitat Huang YT, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80(2):429–36.CrossRefPubMed Huang YT, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80(2):429–36.CrossRefPubMed
16.
Zurück zum Zitat Wakatsuki M, et al. Clinical outcomes of carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix in phase 1/2 clinical trial (protocol 9704). Cancer. 2014;120(11):1663–9.CrossRefPubMed Wakatsuki M, et al. Clinical outcomes of carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix in phase 1/2 clinical trial (protocol 9704). Cancer. 2014;120(11):1663–9.CrossRefPubMed
17.
Zurück zum Zitat Maruyama Y, et al. A review of californium-252 neutron brachytherapy for cervical cancer. Cancer. 1991;68(6):1189–97.CrossRefPubMed Maruyama Y, et al. A review of californium-252 neutron brachytherapy for cervical cancer. Cancer. 1991;68(6):1189–97.CrossRefPubMed
18.
19.
Zurück zum Zitat Lea JS, et al. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol. 2003;91(3):558–62.CrossRefPubMed Lea JS, et al. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol. 2003;91(3):558–62.CrossRefPubMed
20.
Zurück zum Zitat Nakano T, et al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res. 2006;12(7 Pt 1):2185–90.CrossRefPubMed Nakano T, et al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res. 2006;12(7 Pt 1):2185–90.CrossRefPubMed
21.
Zurück zum Zitat Lei X, et al. Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer: long-term treatment results. Int J Radiat Oncol Biol Phys. 2011;81(5):1264–70.CrossRefPubMed Lei X, et al. Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer: long-term treatment results. Int J Radiat Oncol Biol Phys. 2011;81(5):1264–70.CrossRefPubMed
22.
Zurück zum Zitat Tacev T, Ptkov B, Strnad V. Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study. Strahlenther Onkol. 2003;179(6):377–84.PubMed Tacev T, Ptkov B, Strnad V. Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study. Strahlenther Onkol. 2003;179(6):377–84.PubMed
23.
Zurück zum Zitat Bidmead M. Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU report 38. Washington: ICRU; 1985. Bidmead M. Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU report 38. Washington: ICRU; 1985.
24.
Zurück zum Zitat Maruyama Y, et al. Neutron brachytherapy is better than conventional radiotherapy in advanced cervical cancer. Lancet. 1985;1(8438):1120–2.CrossRefPubMed Maruyama Y, et al. Neutron brachytherapy is better than conventional radiotherapy in advanced cervical cancer. Lancet. 1985;1(8438):1120–2.CrossRefPubMed
25.
Zurück zum Zitat van Nagell JR, et al. Phase II clinical trial using californium 252 fast neutron brachytherapy, external pelvic radiation, and extra fascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancer. Cancer. 1986;57(10):1918–22.CrossRefPubMed van Nagell JR, et al. Phase II clinical trial using californium 252 fast neutron brachytherapy, external pelvic radiation, and extra fascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancer. Cancer. 1986;57(10):1918–22.CrossRefPubMed
26.
Zurück zum Zitat Zhang M, et al. Low-dose-rate californium-252 neutron intracavitary after loading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):966–71.CrossRefPubMed Zhang M, et al. Low-dose-rate californium-252 neutron intracavitary after loading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):966–71.CrossRefPubMed
27.
Zurück zum Zitat Maruyama Y, et al. Five-year cure of cervical cancer treated using californium-252 neutron brachytherapy. Am J Clin Oncol. 1984;5(7):487–93.CrossRef Maruyama Y, et al. Five-year cure of cervical cancer treated using californium-252 neutron brachytherapy. Am J Clin Oncol. 1984;5(7):487–93.CrossRef
28.
Zurück zum Zitat Grigsby PW, et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol. 1988;12(4):289–96.CrossRefPubMed Grigsby PW, et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol. 1988;12(4):289–96.CrossRefPubMed
29.
Zurück zum Zitat Niibe Y, et al. High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006–2007. Jpn J Clin Oncol. 2010;40(8):795–9.CrossRefPubMed Niibe Y, et al. High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006–2007. Jpn J Clin Oncol. 2010;40(8):795–9.CrossRefPubMed
30.
Zurück zum Zitat Raju MR, et al. A heavy particle comparative study. Part III: OER and RBE. Br J Radiol. 1978;51:712–9.CrossRefPubMed Raju MR, et al. A heavy particle comparative study. Part III: OER and RBE. Br J Radiol. 1978;51:712–9.CrossRefPubMed
31.
Zurück zum Zitat van Nagell JR, et al. Phase II clinical trial using californium 252 fast neutron brachytherapy, external pelvic radiation, and extra fascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancer. Cancer. 1986;10(57):1918–22.CrossRef van Nagell JR, et al. Phase II clinical trial using californium 252 fast neutron brachytherapy, external pelvic radiation, and extra fascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancer. Cancer. 1986;10(57):1918–22.CrossRef
32.
Zurück zum Zitat Das D, et al. Treatment of cervical carcinoma with high-dose rate intracavitary brachytherapy: two years follow-up study. Asian Pac J Cancer Prev. 2011;12:807–10.PubMed Das D, et al. Treatment of cervical carcinoma with high-dose rate intracavitary brachytherapy: two years follow-up study. Asian Pac J Cancer Prev. 2011;12:807–10.PubMed
33.
Zurück zum Zitat Buranawit K, et al. The treatment outcome of adenocarcinoma of uterine cervix at Phramongkutklao Hospital. J Med Assoc Thai. 2010;93(Suppl 6):S13–21.PubMed Buranawit K, et al. The treatment outcome of adenocarcinoma of uterine cervix at Phramongkutklao Hospital. J Med Assoc Thai. 2010;93(Suppl 6):S13–21.PubMed
Metadaten
Titel
Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma
verfasst von
Yanli Xiong
Jia Liu
Shu Chen
Qian Zhou
Wenjing Xu
Chen Tang
Yonghong Chen
Mei Yang
Xin Lei
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 9/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0670-3

Weitere Artikel der Ausgabe 9/2015

Medical Oncology 9/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.